XML 82 R37.htm IDEA: XBRL DOCUMENT v2.3.0.15
Business Combinations (Narrative) (Details) (USD $)
9 Months Ended1 Months Ended12 Months Ended0 Months Ended
Oct. 02, 2011
Oct. 03, 2010
Sep. 30, 2011
Caliper [Member]
Oct. 02, 2011
Caliper [Member]
Jan. 01, 2012
Minimum [Member]
years
Jan. 01, 2012
Maximum [Member]
years
Oct. 02, 2011
June 2011 Dexela Limited [Member]
Jun. 30, 2011
June 2011 Dexela Limited [Member]
Oct. 02, 2011
May 2011 Labtronics, Inc [Member]
May 31, 2011
May 2011 Labtronics, Inc [Member]
Oct. 02, 2011
May 2011 Geospiza, Inc [Member]
May 31, 2011
May 2011 Geospiza, Inc [Member]
Oct. 02, 2011
April 2011 CambridgeSoft Corporation [Member]
Apr. 30, 2011
April 2011 CambridgeSoft Corporation [Member]
Oct. 02, 2011
March 2011 ID Biological Systems, Inc [Member]
Mar. 31, 2011
March 2011 ID Biological Systems, Inc [Member]
Oct. 02, 2011
March 2011 ArtusLabs, Inc [Member]
Mar. 31, 2011
March 2011 ArtusLabs, Inc [Member]
Oct. 02, 2011
February 2011 Chemagen Biopolymer-Technologie AG [Member]
Feb. 28, 2011
February 2011 Chemagen Biopolymer-Technologie AG [Member]
Oct. 25, 2011
Issuance of Debt [Member]
2021 Notes [Member]
Business Acquisition [Line Items]                     
Tender offer, price per share  $ 10.50                  
Tender offer estimated aggregate consideration   $ 640,000,000                 
Unsecured senior notes, face value                    500,000,000
Proceeds from the issuance of debt instrument                    496,900,000
Debt instrument maturity dateNov. 25, 2021
Unsecured senior notes, interest rate percent                    5.00%
Cash paid to the shareholders       26,100,000 11,400,000 13,300,000 227,400,000 7,700,000 15,200,000 34,600,000 
Additional contingent consideration      12,200,000       3,300,000 15,000,000 20,300,000  
Estimated fair value of contingent consideration      4,600,000       300,000 7,500,000 7,700,000  
Weighted average amortization period (in years)    7.011.0               
Deferred revenue acquisition liability10,500,000     0 315,000 380,000 9,504,000 0 297,000 0  
Decrease in deferred tax liability55,900,000                    
Pre-acquisition deferred revenue66,400,000                    
Total transaction costs$ 4,800,000$ 2,000,000